Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…
KIGALI, Rwanda, Oct. 6, 2025 /PRNewswire/ -- Huawei and Rwanda's Ministry of Education announced the completion of the first phase of…
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
PARIS--(BUSINESS WIRE)--Regulatory News: In September 2025, the state-owned enterprise Navoiyuran (Uzbekistan), the Orano group (France), and the ITOCHU Corporation (Japan)…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
GENEVA, Sept. 24, 2025 /PRNewswire/ -- Just days after officially announcing her candidacy for the FIA Presidency, Swiss racing driver and entrepreneur…
As part of New York Climate Week, LanzaJet's CEO addressed the President of the Republic of Kazakhstan and met with…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…